Clean Levels in SMMT22 hold would be a good remount.
Swing AVWAP against recent highs are holding the stock.
22 gets a 24 push, then pullback to 22 and ideally get a catalyst
SMMT trade ideas
Summit Therapeutics Inc.: Navigating the Bearish Phase After ATHAfter reaching an all-time high of $33.89, Summit Therapeutics Inc. seems to be entering a bearish phase. This shift raises questions about whether the stock will rebound or continue its downward trend. Historically, many biotech and therapeutics companies often experience pullbacks after substantial gains, driven by profit-taking, market corrections, or concerns over future performance.
Investor sentiment can be influenced by various factors, including clinical trial results, regulatory updates, and broader market trends. If Summit Therapeutics can demonstrate strong progress in its pipeline or secure positive news, there may be potential for recovery. However, if uncertainty lingers, the stock could face further challenges. Monitoring key developments and market reactions will be crucial in determining its future direction.
SMMTLike it below $15. Unable to wait, so a bought a small position here at $21. Huge insider purchase of $75M. Hoping to keep it for 1+ year, DYOD risk is it can go to zero. Not a recommendation.
$SMMT Stock Surges on Positive Lung Cancer Drug Trial ResultsShares of Summit Therapeutics (NASDAQ: NASDAQ:SMMT ) surged dramatically, soaring to an all-time high after the biotech firm reported promising results from its Phase 3 trial of ivonescimab, an experimental lung cancer treatment. The news sent the stock up by as much as 75.2% during intraday trading before settling at a 57.5% gain, marking a 54.77% increase by the close. These gains are driven by a powerful combination of strong clinical data and bullish market sentiment, positioning Summit as a rising star in the biotech space.
Clinical Breakthrough: A Game-Changer for Lung Cancer Patients
The Phase 3 trial, known as Harmoni-2, was conducted in China in collaboration with Summit's partner, Akeso. Ivonescimab was tested against Pembrolizumab (Keytruda), a standard-of-care treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with PD-L1-positive tumors. PD-L1 is a protein that helps cancer cells evade the immune system, making it a key target in immunotherapy.
The results were striking: ivonescimab achieved a median progression-free survival (PFS) time of 11.14 months compared to 5.82 months for Keytruda, nearly doubling the time before the disease progressed or led to death. The drug reduced the risk of disease progression or death by 49% compared to other treatments, demonstrating a statistically significant improvement in the trial’s primary endpoint.
This positive data marks a critical validation for Summit's approach, particularly as it outperformed Keytruda across all subgroups, including both low and high PD-L1 expressions and across squamous and non-squamous forms of the disease. This broad efficacy profile could make ivonescimab a highly versatile and sought-after option in the oncology space.
haba CEO Robert Duggan on a 'Historic Moment
Summit Therapeutics CEO Robert Duggan hailed the trial results as a "historic moment" for ivonescimab, calling it the beginning of a shift in the landscape of lung cancer treatment. Duggan stated, “We believe this is the beginning of a landscape shift for treatment options for patients living with cancer.” Summit plans to initiate a multi-regional study of ivonescimab in early 2025, further expanding its global reach.
Ivonescimab’s success in both the Harmoni-2 trial and previous Harmoni-A trials positions it as a potential blockbuster in the making. Earlier trials showed ivonescimab’s efficacy when combined with chemotherapy, even in challenging cases where other monoclonal antibodies had failed.
Technical Analysis: Caution Amidst the Euphoria
On the technical front, NASDAQ:SMMT 's rapid ascent has pushed the stock into overbought territory, with a Relative Strength Index (RSI) of 81.44. Such a high RSI indicates that the stock is ripe for a potential pullback or consolidation as traders digest the news and early profit-takers emerge. The daily chart also shows a gap-up pattern, a phenomenon often filled in subsequent trading sessions as the market corrects its initial exuberance.
While the upward momentum remains strong, traders and investors should be mindful of the possibility of a short-term correction, especially given the sharp run-up. This could offer a more attractive entry point for those looking to capitalize on Summit's long-term potential.
The Road Ahead: Blockbuster Potential and Key Risks
Summit’s ivonescimab could be on the path to becoming a key player in the cancer treatment market, potentially rivaling established therapies like Keytruda. The planned multi-regional trial in 2025 will be crucial in confirming ivonescimab’s efficacy and safety on a global scale.
However, investors should also consider the inherent risks. Early-stage biotechs like Summit face significant hurdles, including regulatory scrutiny, competitive pressures, and the financial burden of advancing clinical trials. Any setbacks in the drug’s development, unexpected adverse events, or delays could impact the company’s stock performance.
Conclusion:
Summit Therapeutics ( NASDAQ:SMMT ) has captured the market’s attention with its impressive trial results for ivonescimab, setting the stage for what could be a transformative journey in lung cancer treatment. While technical indicators suggest caution in the short term, the long-term outlook for NASDAQ:SMMT remains compelling. With continued clinical success and a strategic approach to expansion, Summit is well-positioned to carve out a significant niche in the oncology market. Investors should keep a close watch on the company’s progress as it navigates the complexities of bringing a potentially groundbreaking cancer therapy to market.
As Summit continues to build on this momentum, the stock could offer substantial upside for those willing to weather the inherent volatility of the biotech sector.
$SMMT Support Level for Put SellingLooking to sell some weekly expiration puts on SMMT at the 9 strike price. I think we have room to fall but 9 seems like a nice level to pick up some shares should it make it. Nice premiums.
SMMT - risky Phase 2 play 03 22/2024Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
This is not a financial advice!
Upcoming catalyst on 03/22/2024 - very speculative!
Cup and handle
Recent block buys
Shs. Float 87.26M
Short Float 19.16%
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 4.8 level, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 3.5
TPs approx. 5.7 or 7.5
Most info on the chart.
Trade carefully!
Uptrend becomes a trend lineThe key influencers of trends are the fundamental factors driving the underlying financial asset and market sentiment.
As an example of fundamental factors, the price development of a share can be a reflection of the company's economic strength.
Accordingly, a price increase may be due to the company's success in implementing its business plan or to the forecast of higher sales and profit margins in the future.
SMMT. We are going for the Peak of the Summit.SMMT. We are going for the Peak of the Summit.
High insider value. High institional value. Algo is loading.
After a big run like this, all of these low floats end up dudsAfter a big run like this, all of these low floats end up in the tank. Just speculating that this will follow tradition.
$SMMT Heavy Insider Buying $SMMT insider ownership is crazy high and the CEO owns 162+ Mil shares by himself, that’s crazy confidence!
Insider Ownership 82%
cdn.discordapp.com
media.discordapp.net
www.sec.gov
NASDAQ:SMMT
$SMMT Next Target PT 2 and higherSummit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
SMMT GAP FILL potentialBreaking Key area, and Also major resistance and can go back to down side to the consolidation zone. signs look bullish, but a key area to watch.
Have a Happy Day
SMMT GAP FILL potentialReversal on the 4 hour, from a huge drop in Dec due to poor results for their trials when they combined data. They said 2022 end of 1st quarter they will release an update. They stopped the offering to investors and will give an update later.
52 Week low, Analyst Buy recommendations 6 Buy, 3 Hold, 0 SellThis may be catching a falling knife, but I found SMMT on my scanner after it was down 50% in a day
If you look at all the analyst ratings on this stock there's no reason it should be down where it is right now.
It's down to $2.44 right now at it's 52 week low when just weeks ago it was worth $12 a share.
This is a bargain, it's fallen hard before but there's good reason for it to return to where it was.
$SMMT can rise in the next daysContextual immersion trading strategy idea.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $8.04;
stop-loss — $6.76.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
$SMMT can rise in the next daysContextual immersion trading strategy idea.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $4,11;
stop-loss — $3,70.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!
Long There was a suggestion that the pharmaceutical outsourcing in America is coming back to America so there is 90% up for grabs and they have a good opportunity, also looks like a hammer on the one amateur one hour chart , I could just be hopeful do not copy but feel free to comment .
